Paul Handley
Queen Mary University of London(GB)Barts Health NHS Trust(GB)Royal London Hospital(GB)
Publications by Year
Research Areas
Glycosylation and Glycoproteins Research, Proteoglycans and glycosaminoglycans research, Fibroblast Growth Factor Research, Angiogenesis and VEGF in Cancer, Cancer, Hypoxia, and Metabolism
Most-Cited Works
- → PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models(2011)165 cited
- → Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis(2012)131 cited
- → A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours(2018)99 cited
- → Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues(2013)59 cited
- → Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors(2018)49 cited
- → Antifungal diene in leaves of various avocado cultivars(1999)18 cited